Press release content from BusinessWire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from BusinessWire
Press release content from BusinessWire. The AP news staff was not involved in its creation.

Alcohol Addiction Pipeline Review, H2 2018 - Therapeutic Assessment of 30 Companies - ResearchAndMarkets.com

September 26, 2018

DUBLIN--(BUSINESS WIRE)--Sep 26, 2018--The “Alcohol Addiction - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Alcohol Addiction - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Alcohol Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The Alcohol Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Alcohol Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 11, 5, 1, 20 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Alcohol Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

Introduction Alcohol Addiction - Overview Alcohol Addiction - Therapeutics Development Alcohol Addiction - Therapeutics Assessment Alcohol Addiction - Companies Involved in Therapeutics Development Alcohol Addiction - Drug Profiles Alcohol Addiction - Dormant Projects Alcohol Addiction - Discontinued Products Alcohol Addiction - Product Development Milestones Appendix

Companies Mentioned

AbbVie Inc Addex Therapeutics Ltd Adial Pharmaceuticals LLC Arbor Pharmaceuticals LLC AstraZeneca Plc BioCorRx Inc Bionex Pharmaceuticals LLC Bioprojet SCR Chronos Therapeutics Ltd Corcept Therapeutics Inc Curemark LLC Eli Lilly and Co Ethypharm SA H. Lundbeck AS Heptares Therapeutics Ltd Indivior Plc Johnson & Johnson Kinnov Therapeutics SAS Kyorin Pharmaceutical Co Ltd Lohocla Research Corp Mapreg SAS Montisera Ltd Omeros Corp Opiant Pharmaceuticals Inc Pfizer Inc Silence Therapeutics Plc SK Biopharmaceuticals Co Ltd Syntropharma Ltd Tonix Pharmaceuticals Holding Corp Zynerba Pharmaceuticals Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/f7b6lm/alcohol_addiction?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180926006063/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Addiction Disorders Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/26/2018 05:30 PM/DISC: 09/26/2018 05:30 PM


All contents © copyright 2019 The Associated Press.All rights reserved.